Alliance Global Partners Maintains Buy on Tonix Pharmaceuticals, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners has maintained a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) and raised the price target from $6 to $11.
July 22, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alliance Global Partners has maintained a Buy rating on Tonix Pharmaceuticals and raised the price target from $6 to $11, indicating strong confidence in the company's future performance.
The raised price target from $6 to $11 by Alliance Global Partners suggests a positive outlook for Tonix Pharmaceuticals, likely leading to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100